The Human Leukocyte Antigen (HLA) system plays a pivotal role in immune recognition and is critical for transplantation, vaccine development, and understanding disease susceptibility. OHMX.bio leverages advanced sequencing technologies, particularly long-read sequencing, to provide high-resolution HLA typing. This approach resolves complex HLA loci with unparalleled accuracy, crucial for precise matching in transplantation and for identifying genetic predispositions to immune-mediated diseases.
The immunopeptidome comprises the specific set of peptides displayed by HLA molecules, acting as the ultimate signals for T-cell surveillance and activation. OHMX.bio utilizes advanced proteomic workflows to directly identify and quantify these MHC-associated peptides (both Class I and II) with high sensitivity. This direct profiling is instrumental for the discovery of tumor-specific neoantigens, the development of personalized cancer vaccines, and the precise validation of therapeutic targets.
T-cell receptors (TCRs) and B-cell receptors (BCRs) are the unique molecular identifiers of adaptive immune cells, dictating their antigen specificity. We offer comprehensive TCR and BCR sequencing services, at both bulk and single-cell resolution, to profile immune repertoire diversity, track clonal expansions, and investigate immune responses in various disease contexts, including immuno-oncology, autoimmune disorders, and infectious diseases.
Gene isoforms, arising from alternative splicing, significantly expand the functional diversity of the proteome and play critical roles in immune cell development, activation, and function. OHMX.bio utilizes long-read RNA sequencing to characterize full-length transcripts, enabling unambiguous identification and quantification of splice variants and fusion transcripts. This provides a more complete picture of gene expression and its impact on immune processes.
